Article Text

Download PDFPDF
Letter
Neuronal surface antibodies are common in children with narcolepsy and active movement disorders

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors MPG: conception of the study, acquisition and analysis of data, drafting and proofing of manuscript. FP: acquisition and data analysis, manuscript drafting. LJ: acquisition and data analysis. RL: conception of the study and data acquisition. GP: conception of the study, acquisition and analysis of data. AV: design of the study, analysis of data, drafting and proofing of manuscript.

  • Funding This work was supported by the European Academy of Neurology (Scientific Fellowship to MPG), the Nuffield Department of Clinical Neurosciences, University of Oxford (MPG and AV) and the Department of Biomedical and Neuromotor Sciences (MPG).

  • Competing interests MPG reports no disclosures; FP reports no disclosures;

    LJ reports no disclosures. RL: advisory boards of Biogen, Sanofi Genzyme, Argon Healthcare s.r.l., LT3 s.r.l., PREX s.r.l. and Editree Eventi s.r.l.; lecture fees from Dynamicom Education, SIMG Service, Adnkronos Salute unipersonale s.r.l., DOC Congress s.r.l., SIN foundation, LT3 s.r.l. and First Class s.r.l.; Consultant for Alfasigma and Amicus Therapeutics s.r.l. GP: advisory board for UCB Pharma, Jazz Pharmaceuticals, Bioprojet and Idorsia outside of the submitted work. AV and the University of Oxford hold patents licensed to Athena Diagnostics and Euroimmun AG for MuSK, CASPR2 and LGI1 antibody testing; AV receives a proportion of the royalties.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.